CVE:TLT Theralase Technologies (TLT) Stock Price, News & Analysis C$0.26 0.00 (0.00%) (As of 11/4/2024 05:20 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesInsider Trades About Theralase Technologies Stock (CVE:TLT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Theralase Technologies alerts:Sign Up Key Stats Today's RangeC$0.26▼C$0.2850-Day RangeC$0.17▼C$0.3852-Week RangeC$0.14▼C$0.38Volume117,111 shsAverage Volume121,739 shsMarket CapitalizationC$63.84 millionP/E RatioN/ADividend Yield1,115.38%Price TargetN/AConsensus RatingN/A Company OverviewTheralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. In addition, the company develops TLD-1433, which is in Phase II clinical trial for the treatment of Bacillus Calmette Guérin - Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ. Further, its product candidates include TLC-2000, a superpulsed and visible red laser technology that accelerates healing by reducing pain and inflammation while staying below the Maximal Permissible Exposure limit for tissue, as well as related accessories. Additionally, it researches, develops, manufactures, and distributes controller-less cool laser therapy systems comprising TLC-900, TLC-300, and TLC-100 to healthcare practitioners primarily for the healing of pain. The company has research agreements with the University of Manitoba Medical Microbiology department for the development of a coronavirus vaccine; and the National Microbiology Laboratory and Public Health Agency of Canada for the research and development of a Canadian-based SARS-CoV-2 vaccine. The company is based in Toronto, Canada.Read More… This company will win the AI race (Ad)Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse. You must read this new presentation from Porter Stansberry. Receive TLT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Theralase Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address TLT Stock News HeadlinesTheralase Technologies Inc. (TLT.V)October 27, 2024 | ca.finance.yahoo.comThree Canadian small-caps stocks for a contrarian investmentOctober 11, 2024 | msn.comThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse. November 5, 2024 | Porter & Company (Ad)Latest data from bladder cancer study to propel future growthOctober 10, 2024 | msn.comTheralase’s bladder cancer drug under investigation in clinical studyOctober 7, 2024 | msn.comTheralase Technologies, Inc.: Theralase Extends WarrantsSeptember 19, 2024 | finanznachrichten.deTheralase Technologies, Inc.: Rutherrin Increases Efficacy of Chemotherapy for Lung CancerAugust 28, 2024 | finanznachrichten.deRutherrin(R) Increases Efficacy of Chemotherapy for Lung CancerAugust 28, 2024 | finance.yahoo.comSee More Headlines TLT Stock Analysis - Frequently Asked Questions How have TLT shares performed this year? Theralase Technologies' stock was trading at C$0.18 at the beginning of the year. Since then, TLT stock has increased by 48.6% and is now trading at C$0.26. View the best growth stocks for 2024 here. How were Theralase Technologies' earnings last quarter? Theralase Technologies Inc. (CVE:TLT) posted its earnings results on Monday, August, 12th. The company reported ($0.01) EPS for the quarter. The company earned $0.10 million during the quarter. How do I buy shares of Theralase Technologies? Shares of TLT stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. What other stocks do shareholders of Theralase Technologies own? Based on aggregate information from My MarketBeat watchlists, some other companies that Theralase Technologies investors own include Meta Platforms (META), Tesla (TSLA), NVIDIA (NVDA), Alphabet (GOOG), Netflix (NFLX), Advanced Micro Devices (AMD) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings8/12/2024Today11/04/2024Next Earnings (Estimated)12/04/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Medical Devices Sub-IndustryN/A Current SymbolCVE:TLT CUSIPN/A CIKN/A Webtheralase.com Phone+1-416-6995273FaxN/AEmployees20Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-4,410,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-238.55% Return on Assets-81.88% Debt Debt-to-Equity Ratio20.58 Current Ratio1.21 Quick Ratio3.40 Sales & Book Value Annual SalesC$1.04 million Price / Sales61.39 Cash FlowC$0.01 per share Price / Cash Flow30.45 Book ValueC$0.01 per share Price / Book26.00Miscellaneous Outstanding Shares245,540,000Free FloatN/AMarket CapC$63.84 million OptionableNot Optionable Beta1.36 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report This page (CVE:TLT) was last updated on 11/5/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredMissed Out On Nvidia?Artificial Intelligence is a tool with the potential to create massive distributions of wealth… In fact, it...Unstoppable Prosperity | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Crypto 101 Media | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theralase Technologies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Theralase Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.